Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
High-Intensity Exercise May Protect Against Cognitive Decline
01/26/2023
High-intensity exercise intervals of 6 minutes could protect the brain from age-related cognitive decline and the onset of Alzheimer disease.
High-intensity exercise intervals of 6 minutes could protect the brain from age-related cognitive decline and the onset of Alzheimer disease.
High-intensity exercise...
01/26/2023
Psych Congress Network
News
Social Isolation Linked With Higher Risk of Incident Dementia in US Older Adults
01/26/2023
Social isolation appears common in community-dwelling older adults in the United States and is associated with an increased risk of developing dementia over 9 years, according to a study published in the Journal of the American Geriatrics...
Social isolation appears common in community-dwelling older adults in the United States and is associated with an increased risk of developing dementia over 9 years, according to a study published in the Journal of the American Geriatrics...
Social isolation appears common...
01/26/2023
Psych Congress Network

Advertisement

News
Antipsychotic Prescribing for Children, Adolescents Doubled Over 20 Years
01/25/2023
Over 2 decades, the proportion of antipsychotics prescribed to children and adolescents in England doubled.
Over 2 decades, the proportion of antipsychotics prescribed to children and adolescents in England doubled.
Over 2 decades, the proportion...
01/25/2023
Psych Congress Network
News
Apex Labs Begins Clinical Trial for Take-Home Psilocybin
01/24/2023
Apex Labs has dosed its first patient in a Phase 2b clinical trial in which veterans diagnosed with post-traumatic stress disorder are treated with take-home doses of a synthetic psilocybin formulation to treat depression and anxiety.
Apex Labs has dosed its first patient in a Phase 2b clinical trial in which veterans diagnosed with post-traumatic stress disorder are treated with take-home doses of a synthetic psilocybin formulation to treat depression and anxiety.
Apex Labs has dosed its first...
01/24/2023
Psych Congress Network
News
Technology-Enhanced Screening Identifies Twice as Many People With Psychosis Disorders
01/24/2023
Technology screening identified twice the number of patients with psychosis spectrum disorders compared to clinical judgment, according to a cluster randomized clinical trial published in JAMA Psychiatry.
Technology screening identified twice the number of patients with psychosis spectrum disorders compared to clinical judgment, according to a cluster randomized clinical trial published in JAMA Psychiatry.
Technology screening identified...
01/24/2023
Psych Congress Network

Advertisement

talking with psychiatrist
News
Wrist-wearable Device Biomarkers May Help Predict Adverse Posttraumatic Neuropsychiatric Symptoms
01/23/2023
Wrist-wearable device biomarkers may be useful screening tools for pain, sleep, and anxiety symptom treatment outcomes after trauma exposure.
Wrist-wearable device biomarkers may be useful screening tools for pain, sleep, and anxiety symptom treatment outcomes after trauma exposure.
Wrist-wearable device biomarkers...
01/23/2023
Psych Congress Network
News
Emotional Maltreatment Strongly Linked to Psychiatric Disorders in Children
01/19/2023
Emotional maltreatment may have stronger effects on the psyche of the children and adolescents than physical abuse and neglect, suggest study results published online ahead of print in the journal Child Maltreatment.
Emotional maltreatment may have stronger effects on the psyche of the children and adolescents than physical abuse and neglect, suggest study results published online ahead of print in the journal Child Maltreatment.
Emotional maltreatment may have...
01/19/2023
Psych Congress Network
News
Psychological Distress Tied to All-cause Dementia Risk
01/19/2023
Psychological distress symptoms were associated with a 17% to 24% higher etiological risk of dementia, according to a cohort study recently published in JAMA Neurology.
Psychological distress symptoms were associated with a 17% to 24% higher etiological risk of dementia, according to a cohort study recently published in JAMA Neurology.
Psychological distress symptoms...
01/19/2023
Psych Congress Network

Advertisement

News
Both Massed and Intensive Outpatient Therapy Effective Against PTSD
01/17/2023
Texan military personnel and veterans showed significant improvement at 6 months follow-up.
Texan military personnel and veterans showed significant improvement at 6 months follow-up.
Texan military personnel and...
01/17/2023
Psych Congress Network
News
FDA Approves Bi-Weekly Extended-Release Risperidone for Schizophrenia and Bipolar I
01/16/2023
US FDA approved Rykindo® (risperidone), an extended-release injectable suspension to treat schizophrenia and bipolar I in adult patients.
US FDA approved Rykindo® (risperidone), an extended-release injectable suspension to treat schizophrenia and bipolar I in adult patients.
US FDA approved Rykindo®...
01/16/2023
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use